Floatz logo

Gilteritinib

Blasts 10 Percent or More of Peripheral Blood White Cells

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

684 Active assets in the Blasts 10 Percent or More of Peripheral Blood White Cells cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB

View all 50 →

Same molecule, other indications

Gilteritinib is also rated in:

acute myeloid leukemia, FLT3 internal tandem duplicationDormant
BB
Indicative ·
69 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Dormant
BB
Indicative ·
66 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →